Download
s12885-020-07682-8.pdf 1,76MB
WeightNameValue
1000 Titel
  • Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer
1000 Autor/in
  1. Freytag, Morton |
  2. Kluth, Martina |
  3. Bady, Elena |
  4. Hube-Magg, Claudia |
  5. Makrypidi-Fraune, Georgia |
  6. Heinzer, Hans |
  7. Höflmayer, Doris |
  8. Weidemann, Sören |
  9. Uhlig, Ria |
  10. Huland, Hartwig |
  11. Graefen, Markus |
  12. Bernreuther, Christian |
  13. Wittmer, Corinna |
  14. Tsourlakis, Maria Christina |
  15. Minner, Sarah |
  16. Dum, David |
  17. Hinsch, Andrea |
  18. Luebke, Andreas M. |
  19. Simon, Ronald |
  20. Sauter, Guido |
  21. Schlomm, Thorsten |
  22. Möller, Katharina |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-12-18
1000 Erschienen in
1000 Quellenangabe
  • 20(1):1220
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s12885-020-07682-8 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749503/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Epithelial splicing regulatory protein 1 (ESRP1) and 2 (ESRP2) regulate alternative splicing events of various pre-mRNAs. Some of these targets play a role in cancer-associated processes, including cytoskeleton reorganization and DNA-repair processes. This study was undertaken to estimate the impact of ESRP1 and ESRP2 alterations on prostate cancer patient prognosis.!##!Methods!#!A tissue microarray made from 17,747 individual cancer samples with comprehensive, pathological, clinical and molecular data was analyzed by immunohistochemistry for ESRP1 and ESRP2.!##!Results!#!Nuclear staining for ESRP1 was seen in 38.6% (36.0% low, 2.6% high) of 12,140 interpretable cancers and in 41.9% (36.4% low, 5.3% high) of 12,962 interpretable cancers for ESRP2. Nuclear protein expression was linked to advanced tumor stage, high Gleason score, presence of lymph node metastasis, early biochemical recurrence, and ERG-positive cancers (p < 0.0001 each). Expression of ESRPs was significantly linked to 11 (ESRP1)/9 (ESRP2) of 11 analyzed deletions in all cancers and to 8 (ESRP1)/9 (ESRP2) of 11 deletions in ERG-negative cancers portending a link to genomic instability. Combined ESRPs expression analysis suggested an additive effect and showed the worst prognosis for cancers with high ESRP1 and ESRP2 expression. Multivariate analyses revealed that the prognostic impact of ESRP1, ESRP2 and combined ESRP1/ESRP2 expression was independent of all established pre- and postoperative prognostic features.!##!Conclusions!#!Our data show a striking link between nuclear ESRP expression and adverse features in prostate cancer and identifies expression of ESRP1 and/or ESRP2 as independent prognostic markers with a potential for routine application.
1000 Sacherschließung
lokal Biomarkers
lokal Follow-Up Studies [MeSH]
lokal Aged [MeSH]
lokal RNA-Binding Proteins/metabolism [MeSH]
lokal Humans [MeSH]
lokal Prostatic Neoplasms/metabolism [MeSH]
lokal Prostatic Neoplasms/pathology [MeSH]
lokal Middle Aged [MeSH]
lokal Tissue micro array
lokal Prognosis
lokal ESRP1
lokal Survival Rate [MeSH]
lokal Male [MeSH]
lokal RNA-Binding Proteins/genetics [MeSH]
lokal Biomarkers, Tumor/metabolism [MeSH]
lokal Biomarkers, Tumor/genetics [MeSH]
lokal Prognosis [MeSH]
lokal ESRP2
lokal Case-Control Studies [MeSH]
lokal Prostatic Neoplasms/surgery [MeSH]
lokal Prostatectomy/methods [MeSH]
lokal Research Article
lokal Prostate cancer
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/RnJleXRhZywgTW9ydG9u|https://frl.publisso.de/adhoc/uri/S2x1dGgsIE1hcnRpbmE=|https://frl.publisso.de/adhoc/uri/QmFkeSwgRWxlbmE=|https://frl.publisso.de/adhoc/uri/SHViZS1NYWdnLCBDbGF1ZGlh|https://frl.publisso.de/adhoc/uri/TWFrcnlwaWRpLUZyYXVuZSwgR2VvcmdpYQ==|https://frl.publisso.de/adhoc/uri/SGVpbnplciwgSGFucw==|https://frl.publisso.de/adhoc/uri/SMO2ZmxtYXllciwgRG9yaXM=|https://frl.publisso.de/adhoc/uri/V2VpZGVtYW5uLCBTw7ZyZW4=|https://frl.publisso.de/adhoc/uri/VWhsaWcsIFJpYQ==|https://frl.publisso.de/adhoc/uri/SHVsYW5kLCBIYXJ0d2ln|https://frl.publisso.de/adhoc/uri/R3JhZWZlbiwgTWFya3Vz|https://frl.publisso.de/adhoc/uri/QmVybnJldXRoZXIsIENocmlzdGlhbg==|https://frl.publisso.de/adhoc/uri/V2l0dG1lciwgQ29yaW5uYQ==|https://frl.publisso.de/adhoc/uri/VHNvdXJsYWtpcywgTWFyaWEgQ2hyaXN0aW5h|https://frl.publisso.de/adhoc/uri/TWlubmVyLCBTYXJhaA==|https://frl.publisso.de/adhoc/uri/RHVtLCBEYXZpZA==|https://frl.publisso.de/adhoc/uri/SGluc2NoLCBBbmRyZWE=|https://frl.publisso.de/adhoc/uri/THVlYmtlLCBBbmRyZWFzIE0u|https://orcid.org/0000-0003-0158-4258|https://frl.publisso.de/adhoc/uri/U2F1dGVyLCBHdWlkbw==|https://frl.publisso.de/adhoc/uri/U2NobG9tbSwgVGhvcnN0ZW4=|https://frl.publisso.de/adhoc/uri/TcO2bGxlciwgS2F0aGFyaW5h
1000 Hinweis
  • DeepGreen-ID: ca91b1f60d094297b395031bd4c86c51 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6464645.rdf
1000 Erstellt am 2023-11-16T05:47:23.731+0100
1000 Erstellt von 322
1000 beschreibt frl:6464645
1000 Zuletzt bearbeitet Fri Dec 01 00:31:09 CET 2023
1000 Objekt bearb. Fri Dec 01 00:31:09 CET 2023
1000 Vgl. frl:6464645
1000 Oai Id
  1. oai:frl.publisso.de:frl:6464645 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source